BLOOD CELLS MOLECULES AND DISEASES

Scope & Guideline

Bridging Research and Clinical Insights in Hematology

Introduction

Welcome to your portal for understanding BLOOD CELLS MOLECULES AND DISEASES, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1079-9796
PublisherACADEMIC PRESS INC ELSEVIER SCIENCE
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1995 to 2025
AbbreviationBLOOD CELL MOL DIS / Blood Cells Mol. Dis.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address525 B ST, STE 1900, SAN DIEGO, CA 92101-4495

Aims and Scopes

The journal 'Blood Cells, Molecules and Diseases' primarily focuses on the cellular and molecular aspects of hematology and the pathophysiology of blood-related disorders. It aims to provide a platform for the dissemination of research findings that enhance our understanding of blood cells and their associated diseases, utilizing a variety of methodologies.
  1. Hematopoietic Stem Cell Research:
    This area encompasses studies focusing on hematopoietic stem cells, their differentiation, and their role in various hematological disorders, including aplastic anemia and sickle cell disease.
  2. Genetic and Molecular Characterization of Blood Disorders:
    Research in this scope investigates the genetic mutations and molecular mechanisms underlying various blood disorders such as thalassemia, hemophilia, and leukemias, often employing advanced genomic technologies.
  3. Clinical and Translational Studies:
    The journal publishes clinical studies that evaluate treatment efficacy, disease management strategies, and outcomes in patients with blood diseases, emphasizing the translational aspect of research.
  4. Pathophysiology of Hematological Conditions:
    This includes investigations into the mechanisms of diseases affecting blood cells, such as inflammation, oxidative stress, and immune responses, contributing to a deeper understanding of disease progression.
  5. Innovative Therapeutic Approaches:
    Research on novel therapies, including gene therapy, small molecules, and immunotherapies aimed at treating blood disorders, is a key focus, highlighting advancements in treatment methodologies.
Recent publications in 'Blood Cells, Molecules and Diseases' have highlighted several trending and emerging themes that reflect the evolving nature of hematological research.
  1. Impact of COVID-19 on Hematological Disorders:
    With the ongoing global pandemic, there has been an increase in research examining how COVID-19 affects patients with existing hematological conditions, highlighting the interplay between infectious diseases and blood disorders.
  2. MicroRNA and Epigenetic Regulation:
    Research focusing on the role of microRNAs and epigenetic modifications in the pathogenesis of blood disorders has gained momentum, indicating a growing interest in molecular regulation mechanisms.
  3. Use of Artificial Intelligence and Machine Learning:
    The application of AI and machine learning in diagnostics and treatment planning for blood disorders is emerging, with studies exploring their potential to improve clinical outcomes.
  4. Personalized Medicine in Hematology:
    There is an increasing emphasis on personalized medicine approaches, utilizing genetic profiling to tailor treatments for individual patients, particularly in conditions like sickle cell disease and thalassemias.
  5. Clinical Trials of Novel Therapeutics:
    A significant trend is the increase in clinical trials testing new therapies, particularly in the context of gene therapy and novel pharmacological agents aimed at improving patient outcomes.

Declining or Waning

Over the years, certain themes within 'Blood Cells, Molecules and Diseases' have shown a decline in prominence, reflecting shifts in research focus or changes in the scientific landscape.
  1. Traditional Hematology Techniques:
    There has been a noticeable decrease in studies employing traditional hematology techniques, such as manual blood smear analysis, as the field shifts towards more advanced, automated, and molecular methodologies.
  2. General Reviews on Hematological Disorders:
    While comprehensive reviews were once common, the trend has shifted towards more focused studies that provide novel insights or specific case studies, leading to fewer general reviews being published.
  3. Epidemiological Studies:
    The frequency of broad epidemiological studies on blood disorders has diminished, possibly due to a focus on more localized or specific population studies that yield more actionable insights.

Similar Journals

EXPERIMENTAL HEMATOLOGY

Transforming Hematology with Groundbreaking Research
Publisher: ELSEVIER SCIENCE INCISSN: 0301-472XFrequency: 12 issues/year

EXPERIMENTAL HEMATOLOGY, published by Elsevier Science Inc, is a leading journal in the field of hematology, distinguished by its impactful contributions to the study of blood-related disorders and cellular biology. With an ISSN of 0301-472X and an E-ISSN of 1873-2399, this journal has established a significant presence since its inception in 1973, continuing to be relevant through 2024. It holds a commendable Q1 ranking in Hematology and Q2 in various significant categories including Cancer Research, Cell Biology, Genetics, and Molecular Biology, recognizing its quality and influence in the scientific community. Researchers and professionals can access a wide range of meticulously peer-reviewed articles that promote cutting-edge research and foster collaboration across disciplines. As a vital platform for disseminating innovative findings, EXPERIMENTAL HEMATOLOGY empowers its audience to delve deeper into the complexities of hematological research and brings to light the advances critical for improving patient outcomes.

Inflammation and Regeneration

Fostering collaboration for a healthier tomorrow through science.
Publisher: BMCISSN: Frequency: 1 issue/year

Inflammation and Regeneration is a prominent open-access journal published by BMC, focused on the discerning fields of immunology, cell biology, and regenerative medicine. Since its establishment in 2016, the journal has provided a platform for the dissemination of high-quality research, contributing significantly to the advancement of knowledge in inflammation processes and regenerative therapies. With a remarkable impact reflected in its Q1 quartile rankings in Cell Biology and Immunology for 2023, Inflammation and Regeneration stands out as a leading resource for researchers and practitioners. The journal's commitment to open access ensures that critical findings are readily available to a global audience, fostering collaboration and innovation in the scientific community. With a Scopus ranking that places it in the top 20% of its categories, Inflammation and Regeneration serves as an essential reference for those seeking to stay at the forefront of immunological research and its applications.

FEBS Journal

Elevating Scientific Discourse in Biosciences
Publisher: WILEYISSN: 1742-464XFrequency: 24 issues/year

FEBS Journal is a prestigious, peer-reviewed publication dedicated to advancing the field of biochemistry, cell biology, and molecular biology. Published by WILEY in the United Kingdom, this journal boasts an impressive impact factor and ranks in the top quartile (Q1) across multiple relevant categories, including Biochemistry, Cell Biology, and Molecular Biology, reflecting its significant contribution to scientific research. With an ISSN of 1742-464X and an E-ISSN of 1742-4658, the FEBS Journal publishes original research and comprehensive reviews that push the boundaries of knowledge and innovation in the biosciences. As a vital resource for researchers, professionals, and students alike, the journal offers Open Access options, ensuring that cutting-edge discoveries are accessible to a broad audience. With a publication history converging from 2005 to the present and a robust emphasis on high-quality scholarly work, the FEBS Journal remains an essential platform for the dissemination of significant findings and advancements in the life sciences.

Stem Cell Research

Bridging discovery and clinical innovation.
Publisher: ELSEVIERISSN: 1873-5061Frequency: 6 issues/year

Stem Cell Research is a premier Open Access journal published by ELSEVIER, dedicated to advancing the understanding of stem cell biology. Since its inception in 2007, the journal has provided a platform for the latest research in the fields of Cell Biology, Developmental Biology, and Medicine, with its publication being accessible globally since 2014. Located in the Netherlands, the journal’s comprehensive scope aims to bridge fundamental discoveries with clinical applications, fostering collaboration among researchers and professionals. With a 2023 impact factor reflected in its Q4 ranking in Cell and Developmental Biology and a commendable position in the 64th percentile for General Medicine, Stem Cell Research remains a vital resource for those interested in the dynamic landscape of regenerative medicine. Targeting an audience that includes researchers, practitioners, and students, the journal emphasizes not only the significance of stem cells in medical science but also the ethical considerations and the public discourse surrounding stem cell research. Join the community committed to pioneering the future of stem cell science through rigorous peer-reviewed research.

Blood Research

Transforming Knowledge into Clinical Excellence
Publisher: SPRINGERISSN: 2287-979XFrequency: 4 issues/year

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Enhancing global health with impactful transfusion studies.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

CELLULAR & MOLECULAR BIOLOGY LETTERS

Pioneering Research in Biochemistry and Cell Biology
Publisher: BMCISSN: 1425-8153Frequency: 1 issue/year

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

Advances in Cancer Biology-Metastasis

Fostering Collaboration for Cancer Breakthroughs.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

Journal of Hematology & Oncology

Catalyzing Breakthroughs in Blood Health and Cancer Care
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Hematology Transfusion and Cell Therapy

Advancing knowledge in hematology and cell therapy.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.